Rick Simpson Oil (RSO) in Texas: The Complete Guide by OilWell Cannabis

Understanding Rick Simpson Oil and Its Journey to Texas

When you first hear about Rick Simpson Oil, you might wonder what makes it different from every other cannabis product you’ve encountered, especially here in Texas where our cannabis laws have traditionally been among the most restrictive in the country. The story of RSO begins not with a corporation or a marketing department, but with one man’s desperate search for options when conventional medicine offered nothing left to try.

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He wasn’t a doctor, a scientist, or a medical professional. He was a power engineer and maintenance worker, a blue-collar tradesman whose path into cannabis advocacy began not with research but with personal suffering and a deep distrust of the medical system that had failed him. In 1997, while working at a hospital in Moncton, New Brunswick, Simpson fell from scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and a constellation of post-concussion symptoms that conventional medicine couldn’t adequately resolve. According to Simpson, the medications he was prescribed either failed to help or made his condition worse. He reported that cannabis provided more relief than anything his doctors offered, but when he asked his physician to support or prescribe cannabis, the request was refused.

Simpson’s interest in concentrated cannabis oil deepened after he learned about a 1974 study funded by the National Institute of Health and conducted at the Medical College of Virginia, in which THC was reported to slow or shrink tumors in mice. That study, originally intended to demonstrate harm, became a foundational reference point in Simpson’s later advocacy, even though its findings were never replicated in controlled human cancer trials.

The pivotal moment came in 2003. Simpson reported that three bumps on his arm were diagnosed by his doctor as basal cell carcinoma. Rather than pursuing conventional treatment, he applied concentrated cannabis oil directly to the lesions, covered them with bandages, and waited. According to his account, the bumps disappeared within four days. No independent medical verification of this outcome has been published, and no biopsy confirmation or clinical follow-up has been documented in any peer-reviewed source. Nevertheless, this personal experience became the origin story of Rick Simpson Oil and the foundation of everything that followed.

Now, here’s what matters for you as someone in Texas: Simpson’s account is presented as his personal testimony, not medical evidence. The absence of clinical documentation means these events cannot be evaluated as medical proof. However, his story is historically significant as the catalyst for a global movement around concentrated cannabis oil.

What Traditional RSO Actually Was

Understanding traditional RSO helps you appreciate why modern formulations represent genuine progress. Traditional RSO was defined by Rick Simpson’s specific method and materials, not by laboratory specifications or regulatory standards.

Simpson used high-THC, indica-dominant cannabis strains. He specifically favored heavy, sedating indica genetics and generally recommended against sativa-dominant strains for cancer treatment. He grew his own cannabis or sourced it from growers he trusted. There was no strain standardization, meaning the starting material varied by availability and growing season.

For extraction, Simpson originally used naphtha, a petroleum-based solvent commercially available as lighter fluid, Varsol, or similar products. He later also endorsed 99 percent isopropyl alcohol as an acceptable alternative. He explicitly warned against using other solvents, including butane or acetone, due to safety and purity concerns. Neither naphtha nor isopropyl alcohol is a food-grade solvent, which represents a significant safety difference between traditional RSO and modern extraction methods.

The traditional extraction process involved placing dry or semi-dry cannabis plant material in a container, covering it with solvent, agitating it to dissolve cannabinoids and other fat-soluble compounds from the plant, pouring the solvent through a filter into a collection vessel, repeating a second time with fresh solvent to extract remaining cannabinoids, then evaporating the solvent using a rice cooker or similar heating device. The final oil was transferred into oral syringes for storage and dosing.

Traditional RSO was extremely dark (nearly black), thick, viscous, and tar-like. It had a strong cannabis odor and could carry a faint solvent-residual smell depending on how thoroughly the solvent was purged. The heat involved in solvent evaporation converted essentially all THCa into delta-9 THC, meaning traditional RSO was a decarboxylated, THC-dominant product. Whatever CBD, CBN, CBC, CBG, and other minor cannabinoids the source strain contained were present at their natural ratios, but these were not controlled, measured, or targeted.

Most significantly, every batch of traditional RSO was different. No Certificate of Analysis existed, no cannabinoid quantification was performed, and no contaminant screening was available. Simpson operated before cannabis legalization and the standardized lab-testing infrastructure that came with it. This variability is one of the primary reasons modern RSO formulations have evolved so dramatically.

The Critical Safety Evolution: Solvent-Free Production

One of the most significant safety concerns with traditional RSO production involves residual solvents. Naphtha and isopropyl alcohol are not food-grade solvents. Naphtha in particular is a complex mixture of petroleum hydrocarbons that may contain benzene, toluene, xylene, and other compounds classified as toxic or carcinogenic. Incomplete solvent purging, which is very difficult to verify without analytical chemistry equipment, leaves potentially harmful residues in the finished oil.

Modern cannabis extraction overwhelmingly uses food-grade ethanol or supercritical carbon dioxide (CO₂). These methods allow for much more complete solvent removal, and the finished products can be tested for residual solvents using validated analytical methods such as headspace gas chromatography. This represents one of the most straightforward improvements that the modern regulated cannabis industry has made over traditional RSO production.

At OilWell, we’ve taken this even further. Our RSO is not an extraction product in the traditional sense. It’s a formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in a controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents are present in the finished product. We use organic MCT oil (medium-chain triglycerides) as the carrier base, which is a food-grade lipid carrier that facilitates cannabinoid absorption through sublingual tissue and provides a neutral taste profile, a significant improvement over the tar-like consistency and solvent-residual odor of traditional RSO.

For Texans who may be encountering RSO for the first time, this distinction matters more than you might realize. Texas has always been a state that values straight talk and honest dealing. The difference between solvent-extracted products with potential contamination and solvent-free formulations with verified purity isn’t marketing semantics, it’s a genuine safety consideration.

Why Texas Needs a Different Kind of RSO Conversation

Texas presents unique circumstances when it comes to cannabis access. Our Texas Compassionate Use Program (TCUP) is one of the most restrictive medical cannabis programs in the country. To qualify, you must have one of a limited set of qualifying conditions: cancer, PTSD, epilepsy, autism, terminal illness, ALS, multiple sclerosis, seizure disorders, or incurable neurodegenerative diseases. Even with a qualifying condition, you must find a physician registered with the program who is willing to certify you, then visit a licensed dispensary. The products available through TCUP contain low THC concentrations and are significantly more expensive than what’s available in other states.

This regulatory environment has left many Texans searching for alternatives. We’ve built OilWell Cannabis to serve precisely these people: Texans who want access to cannabinoid products but who either don’t qualify for TCUP, can’t find a registered physician, prefer the privacy of ordering from home, or simply want formulations that go beyond what TCUP dispensaries currently offer.

Our approach is different from both traditional RSO and TCUP dispensary products. Where traditional RSO was unstandardized and solvent-extracted, our formulations are precisely measured and solvent-free. Where TCUP products are THC-only and require medical certification, our products combine seven cannabinoids in specific ratios and require only that you’re 21 or older.

This raises a question we hear constantly from Texans: “How is this legal?”

Farm Bill Compliance and the Legal Framework for Texans

The 2018 Farm Bill (Agriculture Improvement Act) legalized hemp and hemp-derived products containing less than 0.3 percent delta-9 THC by dry weight at the federal level in the United States. This legal framework is the foundation of our product design.

Our RSO Sublingual Oil contains only 90 milligrams of delta-9 THC in the entire 30 mL bottle, approximately 3 milligrams per milliliter, well under the 0.3 percent threshold. All cannabinoids in the formula are hemp-derived. The product is legal under federal law and available without a medical card.

Here’s where it gets interesting for Texans: THCa, tetrahydrocannabinolic acid, is the acidic, non-psychoactive precursor to delta-9 THC. It’s not itself delta-9 THC. This distinction is legally significant. THCa is Farm Bill compliant at the point of sale because it has not been converted to delta-9 THC.

The practical significance of this framework is substantial. You can decarboxylate THCa into delta-9 THC at home by heating the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container. This converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC in the formula, this produces approximately 1,405 milligrams of total delta-9 THC, giving the product psychoactive potency comparable to traditional RSO, entirely at your discretion after purchase.

This means the same product can function as a non-psychoactive anti-inflammatory (used raw) or as a full-potency cannabinoid product (after home decarboxylation). You control the decision. The product is legal everywhere hemp-derived products with less than 0.3 percent delta-9 THC are permitted.

Important legal notice: THCa converts to delta-9 THC when heated. You are responsible for understanding and complying with your local laws regarding cannabinoid products. We ship with full documentation, Certificates of Analysis, and receipts. International customers accept all customs and legal responsibility.

The OilWell Story: From the Border to Houston

We believe you should know who you’re dealing with, especially in Texas where trust and reputation matter. OilWell Cannabis was founded by Colin Valencia in Houston, Texas. Colin grew up in McAllen, right across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa area, known as the Borderplex, is one of the most economically challenged and dangerous regions along the U.S.-Mexico border. McAllen is a city of contrasts: vibrant culture and a thriving retail sector, yet deeply affected by poverty and limited opportunities outside the retail and healthcare industries. Reynosa, on the other hand, is an industrial hub plagued by violence and cartel activity, making it a harsh environment for anyone growing up there.

Colin’s childhood in McAllen was marked by exposure to both the opportunities and the challenges of life along the border. Early on, he learned to hustle, taking on risky work transporting items across the border for various groups. Those early experiences exposed him to the complexities and dangers of life in that region. Many of his best friends have been killed or are in prison because of the associated dangers. He has faced every form of violence imaginable, both in the streets and across the border. By sixteen, one way or another, he had to leave home for good.

Despite the dangers, Colin did not fall into the darkest paths available to him, like selling harder substances. Instead, he focused on cannabis, seeing it as a safer and more beneficial alternative. He grew up in the traditional cannabis world long before legalization, learning the plant intimately while operating in the shadows. Over time, he transitioned from those early, risky ventures to creating a legal, legitimate business in an industry he believes in.

Colin later became a formally trained software engineer and did custom development work for Baylor College of Medicine, one of the most prestigious medical institutions in the Texas Medical Center. That combination, deep cannabis plant knowledge plus medical-grade technical precision, would eventually define OilWell’s approach.

The company’s origin story begins with a dog named Bentley. Bentley was more than just a pet; he was family, a companion who stood by Colin through the toughest times. When Bentley fell seriously ill, veterinarians delivered the verdict no pet owner wants to hear: euthanasia was the only humane option. Bentley was paralyzed in his back legs. They said the pain medications would destroy his internal organs, causing him more pain and suffering. The choice was painful prolonged decline or immediate mercy killing.

But giving up on Bentley was not an option. Colin had already faced too much loss and seen too much suffering in his life. Bentley was a fighter, just like him, and Colin wasn’t ready to let him go. In a desperate search for alternatives, he stumbled upon the healing properties of CBD through a question that changed everything.

A kind-hearted rescue worker named Jessica asked Colin: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

Colin had cannabis experience, but it was recreational. Getting high. He had never explored the therapeutic and medicinal applications. Jessica’s question exposed a blind spot that would become a mission.

Determined to save Bentley, Colin learned to create CBD golden paste, a specialized cannabinoid formula for pets. It wasn’t a cure, but it was a lifeline, and it was hope. And that hope delivered something veterinary medicine said was impossible: Bentley got up. He walked over to Colin and brought him his ball to play. It was a miracle. From paralyzed and facing euthanasia to fetching his ball. Dogs don’t respond to placebo. This was cannabinoid medicine doing what pharmaceuticals couldn’t.

Bentley lived another ten years, passing naturally at age twenty. During those ten years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced. Neurodegeneration led him to understand CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection. Dementia led him to CBC’s role in neurogenesis. Glaucoma led him to THC’s CB1 agonism for intraocular pressure reduction. Crippling arthritis led him to develop multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously.

Single cannabinoids weren’t enough. Bentley’s evolving conditions required multi-cannabinoid synergy. CBD alone couldn’t address neurodegeneration and dementia and glaucoma and arthritis simultaneously. Minor cannabinoids like CBG, CBN, and CBC became critical as Bentley aged. Pharmaceutical precision mattered. Bentley’s life depended on formula accuracy, not guesswork.

Bentley’s journey was Colin’s entry into the world of cannabis beyond just getting high. It became a mission to create real solutions that help alleviate pain and suffering, not just for pets but for people as well. Bentley’s story is the foundation of OilWell Cannabis, driving its commitment to quality, innovation, and compassionate care.

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey, a feat that is notoriously difficult and dangerous, using the cannabinoid knowledge he had developed keeping Bentley alive. The Peace Gummies formula that became an OilWell product was created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, OilWell also offers the Peace Gummies formula in a vape form, which Colin personally uses to manage his insomnia and severe PTSD. This isn’t theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills don’t.

Over time, the therapeutic benefits of cannabis that Colin first discovered through his efforts to save Bentley became the core of his work. He has developed formulas that doctors use for conditions like Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. His focus has always been on making cannabis accessible and effective for everyone, including vegans, diabetics, and those with specific health needs.

ABC13 KTRK Houston, Houston’s number-one news source, featured Colin and OilWell Cannabis in seven comprehensive news segments spanning 2019 to 2023, covering Texas marijuana law, Delta-8 legal analysis, COVID-19 community health leadership, criminal justice reform, and cannabis business pioneering. Colin was repeatedly selected as the primary industry expert for cannabis policy and product coverage in America’s fourth-largest city.

His quote from the first ABC13 feature in September 2019 captures our philosophy: “I’m not trying to sell people snake oil. I’m not trying to sell people hope. But there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

Today, we operate from Montrose in Houston, Texas, at 810 Richmond Avenue, Houston, TX 77006. The company has been operating since 2019, generates approximately one million dollars in annual revenue, maintains a near-5.0 Google rating, and is Texas DSHS licensed. Our products aren’t mass-produced; they’re carefully crafted with a personal touch, from the artwork on the packaging to the formulations inside. All artwork, formulations, and packaging are created in-house in Houston, using only our own recipes and ideas. Colin brings Houston grit, McAllen roots, and a builder’s mindset to the company, but the posture stays simple: make products with intent, answer directly, and never pretend cannabis is right for everyone.

The OilWell RSO Philosophy: Four Core Principles

Our RSO isn’t traditional Rick Simpson Oil. It’s a formulated, multi-cannabinoid product informed by the RSO tradition but departing from it in ways that are deliberate, evidence-motivated, and designed to solve the problems that limited Rick Simpson’s original vision.

First, accessibility over gatekeeping. No medical card is required. Anyone age twenty-one or older can purchase. We ship nationwide across the United States and internationally to customers who verify local legality. Rick Simpson believed medicine should be accessible to everyone; we built a product and distribution model that makes that accessible legally.

For Texans specifically, this matters enormously. Our state’s TCUP program excludes the vast majority of people who might benefit from cannabinoid products. Chronic pain patients without a specific qualifying diagnosis, people with anxiety disorders that don’t meet PTSD criteria, individuals with sleep issues, those seeking general wellness support; none of them qualify under current Texas law. We’ve built an alternative pathway.

Second, patient-controlled potency. THCa is sold in its acidic, non-psychoactive form. You decide whether to use it raw for non-psychoactive benefits or to decarboxylate it into delta-9 THC for full psychoactive potency. Simpson believed patients should control their own medicine; we engineered a product that puts that control in your hands through chemistry rather than rhetoric.

This is particularly valuable in Texas where public intoxication laws, workplace drug testing, and driving regulations create real concerns about psychoactive cannabinoid use. The ability to use the raw product for daytime therapeutic benefit without impairment, then decarboxylate a separate portion for evening use, gives you options that traditional RSO never offered.

Third, open-source formulas. We publish our complete formulas publicly, every cannabinoid, every milligram amount, every percentage, so that anyone who can’t afford our products can source ingredients and make their own version. Simpson gave his oil away for free and taught people how to make it; we adapted that ethos for the modern cannabinoid marketplace by selling a professionally manufactured product and publishing the recipe.

This matters in a state where economic disparities are significant and many people lack health insurance. If you can afford $129.99 for our sublingual oil or $49.99 for our vape cartridge, you can buy a professionally manufactured, lab-tested product. If you can’t, you can take the open-source formula we publish, source the individual cannabinoid distillates and isolates, and make your own.

Fourth, evidence-informed, not evidence-overstating. The research foundation in this document represents our commitment to honest education about what the science actually says. Simpson operated without access to peer-reviewed literature or clinical trial data; we have that access and use it to distinguish between what is well-supported, what is emerging, and what is overstated.

Why Our Formulas Diverge from Traditional RSO

Our formulations depart from traditional RSO in several deliberate, evidence-motivated ways that matter for real-world use.

Multi-cannabinoid approach. Traditional RSO relied on whatever single strain the maker grew or sourced. Our formulas intentionally include seven cannabinoids: CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC. The entourage-effect literature suggests potential benefit from cannabinoid diversity, even though robust clinical proof of whole-formula synergy remains limited. What we know from real-world formulation experience is that single cannabinoids often aren’t enough for complex conditions. Bentley’s evolving needs taught us that multi-cannabinoid synergy matters.

Terpene preservation and addition. Traditional RSO had essentially no terpene content due to solvent and heat destruction. We include live terpenes at 5 percent with a specific seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. Terpene bioactivity is plausible and supported at the preclinical level, even if human clinical confirmation for cannabis-specific terpene effects is still developing. The aromatic and flavor profile matters for the actual experience of using the product, not just the potential therapeutic effects.

THCa as a separate ingredient. Traditional RSO fully decarboxylated everything, converting all THCa into delta-9 THC. Our sublingual formula includes THCa at 1,500 mg as a distinct ingredient, preserving the acidic precursor because the THCa literature suggests potentially relevant non-psychoactive bioactivity that is lost when THCa converts to THC.

For Texans who need daytime functionality, this is crucial. You can use the raw product for anti-inflammatory and neuroprotective benefits without psychoactive impairment, then decarboxylate a separate portion for evening use when impairment is acceptable.

Reduced delta-9 THC dominance. Traditional RSO was overwhelmingly delta-9 THC, often 60 to 90 percent of total cannabinoid content. Our sublingual formula uses delta-9 THC at only 90 mg while incorporating delta-8 THC at 6,000 mg and distributing the remaining cannabinoid content across CBD (4,500 mg), CBG (3,000 mg), CBN (750 mg), and CBC (750 mg). This reflects the broader cannabinoid research landscape rather than a single-compound dominance model.

The practical effect is smoother, more balanced effects. Delta-8 THC provides cannabinoid activity with reportedly less anxiety and paranoia than delta-9 THC for many users. The combination creates therapeutic potential with better tolerability.

Product format innovation. Simpson envisioned only one format: an oral oil administered from a syringe. We offer both a 30 mL sublingual oil and a 1-gram vape cartridge, each with its own format-specific formulation acknowledging that different delivery routes have different pharmacokinetic profiles.

Understanding the Cannabinoids in Our Formula

Every cannabinoid in our formula has its own evidence profile, and we believe you deserve honest information about each one.

CBD (Cannabidiol)

CBD has the strongest human evidence of any compound in our formula, especially when studied as a purified product rather than as a loose wellness ingredient. The clearest evidence is for seizure disorders, where purified CBD has FDA approval as Epidiolex for certain rare epilepsies. A 2024 systematic review and meta-analysis covering 316 participants across eight articles reported a statistically significant anxiolytic signal for anxiety, though the authors stressed that more trials are needed before broad conclusions are justified. A 2024 systematic review of clinical and preclinical CBD monotherapy studies concluded that the pain literature is promising but heterogeneous, with trial quality and consistency still limiting confidence in broad analgesic claims. A 2023 insomnia review found that the sleep literature remains methodologically weak. A 2023 systematic review and meta-analysis found a real signal for liver enzyme elevation and possible drug-induced liver injury in some CBD contexts, which is especially relevant for concentrated oral products and polypharmacy settings.

CBD is the most evidence-developed nonintoxicating cannabinoid in our formula, but even here, strong evidence is concentrated in specific indications rather than broad generalized wellness claims.

CBG (Cannabigerol)

CBG’s evidence profile is mostly review-level and preclinical; human evidence remains sparse. CBG is the biosynthetic precursor to several major cannabinoids and appears pharmacologically distinct from both THC and CBD. Review literature describes interactions spanning cannabinoid receptors as well as alpha-2 adrenoceptors and 5-HT1A-related signaling, which makes it mechanistically interesting but not yet clinically established. Published reviews discuss possible relevance to neurologic disorders, inflammatory bowel disease, and antibacterial activity, but these are primarily pharmacology-led hypotheses or preclinical findings rather than mature human therapeutic conclusions. One key point from the 2021 pharmacology review is that CBG is already being sold commercially while the evidence base remains thin, which means claims frequently outrun the science.

CBG is a serious research topic, but at present it should be described as a promising minor cannabinoid with limited clinical validation rather than as a proven therapeutic cannabinoid.

Delta-8 THC

Delta-8 THC is pharmacologically relevant, psychoactive, and much less clinically characterized than delta-9 THC. A 2022 review concluded that delta-8 THC and delta-9 THC have broadly similar pharmacokinetic and pharmacodynamic behavior. Delta-8 THC is a partial CB1 agonist with cannabimimetic activity in animals and humans, but it appears less potent than delta-9 THC, likely in part because of weaker CB1 affinity. A 2023 scoping review found that much of the delta-8 evidence base is still dominated by animal studies, product chemistry, use reports, and public-health concerns rather than strong modern human trials. Commercial delta-8 interest is tied to greater stability and easier synthesis relative to naturally scarce plant levels, which is part of why product quality and lab-testing questions matter.

Delta-8 THC should be treated as a psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, and more manufacturing-quality uncertainty than many consumers realize.

THCa (Tetrahydrocannabinolic Acid)

THCa is important chemically and formulation-wise, but still low on direct human therapeutic evidence. THCa is the acidic precursor of THC and may represent a very large share of the THC-related content in raw plant material. The key formulation issue is that THCa decarboxylates into THC during heating and can also change over time during storage and processing. The major review source stresses that THCa itself does not produce the psychoactive effects associated with THC in humans, but the distinction only holds if the molecule stays in its acidic form and is not substantially decarboxylated. In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but these aren’t equivalent to established human outcomes.

THCa is best understood as a highly relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, and storage.

Delta-9 THC

Delta-9 THC has the strongest human evidence of the psychoactive cannabinoids, but also the clearest adverse-effect burden. The National Center for Complementary and Integrative Health identifies THC-containing cannabinoid medicines as relevant to chemotherapy-related nausea and vomiting, appetite and weight loss in HIV/AIDS, and some multiple-sclerosis and pain-related outcomes. A 2022 systematic review of cannabis-based products for chronic pain found that products with high THC content or roughly comparable THC:CBD ratios may provide short-term pain benefit, but they also increased dizziness, sedation, nausea, and treatment discontinuation due to adverse events. Classic pharmacokinetic review literature shows that inhaled THC usually produces effects within seconds to minutes, peaks roughly within 15 to 30 minutes, and tapers over a few hours; oral THC has later onset, later peak, and longer duration, which matters for both benefit and overconsumption risk. A 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis or schizophrenia outcomes and cannabis use disorder, with additional concerning signals for anxiety and depression in nontherapeutic settings.

Delta-9 THC has legitimate therapeutic relevance in some settings, but it also carries the clearest intoxication, psychiatric, and dose-related safety liabilities in our formula.

CBN (Cannabinol)

CBN’s evidence profile is weak; marketing has clearly moved ahead of the data. CBN is often marketed for sleep and sedation, but the clinical support is far thinner than the market suggests. A 2021 narrative review on CBN and sleep screened 99 human-study abstracts, reviewed eight full-text articles, and found no clinical trials using validated sleep questionnaires or formal polysomnography that could substantiate strong sleep-promoting claims for CBN. The 2024 updated review on cannabis and sleep concluded that overall cannabinoid sleep research still does not match the scale of real-world use. Downstream cannabinoid degradation pathways matter here as well; review literature on THCa notes that THC can further degrade toward CBN under certain conditions, which helps explain why CBN is often discussed in aging or oxidized cannabis chemistry contexts.

CBN is one of the clearest examples in this field where cultural reputation is stronger than the current clinical evidence base.

CBC (Cannabichromene)

CBC’s evidence profile is emerging, intriguing, and still overwhelmingly preclinical or review-based. A 2024 focused review on CBC argues that it has distinct pharmacodynamics, pharmacokinetics, and receptor behavior relative to better-known cannabinoids, and highlights antinociceptive, antibacterial, and anti-seizure areas as especially interesting research targets. Review literature summarizing CBC in animal and in vitro work reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, and possible neurobiological or antiproliferative relevance, but these signals aren’t yet strong evidence for patient-facing claims. The 2024 CBC review explicitly notes that over-the-counter CBC products are already being sold despite little evidence establishing clinical efficacy or safety.

CBC belongs in the category of scientifically credible minor cannabinoids that deserve more research, not in the category of already-validated clinical actives.

Understanding the Terpenes in Our Formula

Terpene claims need even stricter interpretation than cannabinoid claims. Much of the terpene literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models rather than controlled human studies of cannabis formulations. Terpene bioactivity is plausible and sometimes compelling, but robust proof of clinically meaningful entourage effects in humans remains limited.

Limonene (citrus-bright) is largely supported by review and preclinical literature, with useful safety literature. A 2021 review describes limonene as a multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory, and other possible activities, but the overwhelming share of those claims comes from nonhuman or non-cannabis literature. Limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens. Limonene is biologically active and widely discussed, but cannabis-specific therapeutic claims should stay conservative unless directly supported in humans.

Myrcene is mostly supported by preclinical evidence with very limited human research. A 2021 myrcene review describes anxiolytic, antioxidant, anti-inflammatory, and analgesic properties and discusses possible mechanisms, but explicitly states that human studies are lacking. Myrcene is often invoked in consumer language as a proven sedating terpene that explains couch-lock or sleep effects, but that’s a stronger claim than the human evidence currently supports. Myrcene is a plausible bioactive terpene, but compound-specific clinical claims about mood, pain, or sedation remain far ahead of definitive human proof.

Caryophyllene (β-caryophyllene, pepper/spice) is among the most mechanistically interesting terpenes because of direct cannabinoid-system relevance, but is still mostly preclinical. A 2021 focused review describes beta-caryophyllene as a selective CB2 receptor agonist, which is unusual and makes it especially relevant when discussing cannabis terpenes in pharmacologic rather than purely aromatic terms. Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective, and related actions are repeatedly discussed in the review literature, but human clinical confirmation remains limited. Beta-caryophyllene is arguably the strongest candidate for a terpene with cannabinoid-system significance, but it still shouldn’t be described as clinically proven for the outcomes commonly attributed to it.

Pinene (forest-fresh) has promising preclinical literature with weak human clinical confirmation. A 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, and neuroprotective signals that justify future study, but emphasized that evidence is mostly preclinical and that well-designed clinical trials are lacking. Claims that pinene reliably improves memory, sharpens attention, or counterbalances THC-related cognitive effects remain interesting hypotheses rather than settled clinical facts.

Linalool (floral, lavender) has substantial preclinical interest with limited direct clinical confirmation. Linalool is repeatedly discussed in relation to stress, mood, and brain-health pharmacology. The 2021 brain-health review found enough preclinical signal to justify continued investigation in neurological and psychiatric contexts, while still emphasizing the lack of robust human trials. Separate review literature discusses possible antidepressant mechanisms and neuropharmacologic relevance. As with limonene, oxidized linalool hydroperoxides are recognized allergens in dermatitis literature.

Humulene (earthy, woody) is translationally interesting but still early. A 2024 scoping review analyzed 340 articles and found broad preclinical evidence for anti-inflammatory and other biologic effects, with some rodent work even suggesting cannabimimetic properties via CB1 and adenosine A2a pathways. Those findings are valuable for hypothesis generation, but they don’t yet establish consistent human efficacy across pain, inflammation, or mood outcomes.

Terpinolene (piney, fruity, sparkling) is one of the least clinically characterized terpenes in our formula. A 2021 terpinolene review screened 2,449 records and included 57 studies, concluding that terpinolene has a range of reported biological effects but that the evidence base is still dominated by in silico, in vitro, and animal studies rather than human trials. Even recent cannabis entourage reviews frame terpene benefits as exploratory, not as established compound-specific clinical effects.

Open-Source Formulas: Why We Publish Everything

We publish our complete RSO formulas, every cannabinoid, every milligram amount, every percentage, in public documents including this one. The rationale is straightforward: if someone can’t afford our products, they can see exactly what the formula contains, source the individual cannabinoid distillates and isolates, and make their own version. The formulas in this document are the open-source formulas.

This is a direct echo of Rick Simpson’s original ethos. Simpson gave his oil away for free and taught people how to make it. He never patented his method. He never charged patients. We adapted that ethos for the modern cannabinoid marketplace: we sell a professionally manufactured, lab-tested, standardized product for those who want it, and we publish the complete recipe for those who want to make it themselves.

The open-source philosophy didn’t start with RSO; it started with Bentley. On our About Us page, Colin published the actual CBD golden paste recipe that saved Bentley’s life, so that any pet owner facing a similar crisis could make it themselves.

CBD Golden Paste Recipe for Pets:

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1 to 2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on the size and needs of the pet; consult with a veterinarian)

Instructions:

1. Mix the turmeric and water. In a saucepan, combine the turmeric powder and water, stirring over low heat. Stir continuously until it forms a thick paste. This should take about 7 to 10 minutes. Add a little more water if it becomes too thick.
2. Add the coconut oil and pepper. Once you have a thick paste, add the coconut oil and freshly ground black pepper. Stir until all ingredients are thoroughly mixed.
3. Cool and store. Allow the paste to cool, then transfer it to a jar with a lid. Store it in the refrigerator for up to two weeks.
4. Dosage. Add a small amount of CBD oil to the paste before giving it to the pet, adjusting the dosage based on their weight and health needs. Start with a low dose and gradually increase as needed.

Serving suggestion: Mix a small amount of the golden paste with the pet’s food once or twice a day. Monitor the pet for any changes and consult with a veterinarian if there are any concerns. Always consult with a veterinarian before starting any new supplement regimen for a pet.

This recipe, published for free years before the RSO formulas were open-sourced, demonstrates that the pattern is consistent. Colin gave away the formula that saved Bentley before he gave away the formula designed for people. The open-source ethos isn’t a marketing strategy. It’s the foundational behavior of the company.

The Decarboxylation Choice: Patient-Controlled Potency

Traditional RSO was always fully decarboxylated. The heat of solvent evaporation converted all THCa into delta-9 THC, leaving you with no choice about psychoactivity. The oil was always psychoactive.

Our sublingual formula contains 1,500 milligrams of THCa in its acidic, non-psychoactive form. This creates three distinct usage options for you:

Option 1: Raw, no heat. All 1,500 milligrams stays as THCa, completely non-psychoactive. The THCa evidence profile describes potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism. This option is compatible with work, driving, and daytime use with zero psychoactive impairment.

This is ideal for Texans who need therapeutic support during work hours, parents who need to stay functional for childcare, anyone subject to workplace drug testing who wants anti-inflammatory benefits without psychoactive effects, or people who simply prefer to remain clear-headed while getting cannabinoid support.

Option 2: Fully activated, home decarboxylation. Heat the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container. This converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC already in the formula, this yields approximately 1,405 milligrams of total delta-9 THC. Combined with 6,000 milligrams of delta-8 THC, the activated product achieves psychoactive potency comparable to traditional high-THC RSO, 100 percent legally, because decarboxylation occurs at your discretion after purchase.

You may also transfer a controlled portion of the oil from the original bottle into a second empty oven-safe glass container, decarboxylating only what you intend to use and preserving the remainder in its raw THCa form. This gives you complete control over your experience: raw for daytime function, decarboxylated for evening relaxation.

Option 3: Vape, auto-decarboxylation. Our RSO Vape Cartridge vaporizes at 400 to 450°F, which instantly converts THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids. This is the fastest-onset RSO delivery method available.

The conversion chemistry: THCa has a molecular weight of 358.47 g/mol. The conversion ratio is approximately 1 milligram THCa = 0.877 milligrams delta-9 THC after decarboxylation, reflecting the loss of a CO₂ molecule during the reaction.

This design puts the potency decision entirely in your hands, aligning with Rick Simpson’s principle that patients should control their own medicine, but implementing that principle through actual product chemistry rather than a one-size-fits-all approach.

RSO Sublingual Oil: Complete Formula and Specifications

Our RSO Sublingual Oil is $129.99 for a 30 mL bottle (1 fl oz), delivering 16,590 mg total cannabinoids at 553 mg per mL across seven cannabinoids.

Cannabinoid	Amount
CBD	4,500mg
CBG	3,000mg
Delta-8 THC	6,000mg
THCa	1,500mg
Delta-9 THC	90mg
CBN	750mg
CBC	750mg
Total Cannabinoids	16,590mg

• Live Terpenes: 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)
• Format: 30mL bottle
• Active cannabinoids per mL: 553mg
• Organic MCT oil base
• Graduated dropper for precise dosing in 0.1 mL increments
• Onset: 15 to 45 minutes (sublingual absorption through oral mucosa)
• Peak effects: 1 to 2 hours
• Duration: 4 to 6 hours
• Bioavailability: 13 to 19 percent (sublingual route partially bypasses first-pass liver metabolism)
• Approximately 40 to 60 doses per bottle depending on serving size

This isn’t a CBD product with trace amounts of other cannabinoids. It’s a genuine multi-cannabinoid formulation with meaningful amounts of all seven compounds. The 4,500mg of CBD provides anxiolytic and anti-inflammatory support. The 3,000mg of CBG adds neuroprotective and potential cognitive benefits. The 6,000mg of delta-8 THC delivers cannabinoid activity with reportedly smoother effects than delta-9 THC. The 1,500mg of THCa gives you daytime functionality in raw form or extra potency if decarboxylated. The 90mg of delta-9 THC stays within Farm Bill limits while still contributing to the overall effect. The 750mg of CBN supports sleep architecture. The 750mg of CBC adds potential neurogenic and anti-inflammatory support.

RSO Vape Cartridge: Complete Formula and Specifications

Our RSO Vape Cartridge is $49.99 for a 1-gram cartridge with 900mg+ total cannabinoids using the same six-cannabinoid ratio in a format optimized for vaporization.

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live Terpenes: 5%+
• Format: 1 Gram cartridge
• 510-thread universal battery compatibility
• Onset: 1 to 2 minutes (fastest cannabinoid delivery method)
• Peak effects: 10 to 15 minutes
• Duration: 2 to 4 hours
• Bioavailability: 10 to 35 percent (variable, dependent on inhalation technique)
• Automatic THCa decarboxylation at vaping temperature (400 to 450°F)

The vape format serves different needs than sublingual. Where sublingual provides sustained relief over 4 to 6 hours, the vape delivers rapid onset for acute situations. Where sublingual offers precise dosing with a graduated dropper, the vape provides convenience and portability. Many of our customers use both: sublingual for baseline daily support, vape for breakthrough moments.

When to Use Each Format

Use case	Recommended format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration
Maximum bioavailability	Sublingual	13-19% absorption
Portability and discretion	Vape	Compact, no measuring required
Precise dosing control	Sublingual	Graduated dropper in 0.1 mL increments
Daytime non-psychoactive use	Sublingual (raw, no heat)	THCa stays inactive, zero impairment
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC

Competitive Comparison: OilWell RSO vs. Alternatives

Let’s be direct about how our product compares to what else is available to Texans.

OilWell RSO vs. Texas TCUP Dispensary RSO (e.g., Texas Original)

Dimension	TCUP dispensary RSO	OilWell RSO
Cannabinoid profile	THC-only (approx. 420 mg THC per 0.5 g syringe)	7 cannabinoids: CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC
CBG content	0 mg	3,000 mg
CBN content	0 mg	750 mg
CBC content	0 mg	750 mg
Patient-controlled potency	No — always fully psychoactive	Yes — THCa non-psychoactive until heated by customer
Access requirements	TCUP medical card with qualifying condition	Age 21+ only, no medical card required
Qualifying conditions	Cancer, PTSD, epilepsy, autism, terminal illness, ALS, MS, seizure disorders, incurable neurodegenerative diseases	None required
Delivery	Must travel to physical dispensary location	Same-day delivery Houston, nationwide and international shipping
Farm Bill compliant	No — state medical cannabis program	Yes — less than 0.3% delta-9 THC

OilWell RSO vs. Hemp CBD RSO (e.g., Lazarus Naturals)

Dimension	Lazarus Naturals RSO (10 mL, 1,000 mg)	OilWell RSO (30 mL, 16,590 mg)
Total cannabinoids	1,000 mg	16,590 mg
CBD content	Approximately 950 mg	4,500 mg
CBG content	15.5 mg	3,000 mg
CBN content	0.7 mg	750 mg
Delta-8 THC	0 mg	6,000 mg
THCa (convertible to delta-9 THC)	Minimal	1,500 mg (converts to approximately 1,315 mg delta-9 THC)
Psychoactive option	No meaningful psychoactive effect	Yes — via THCa decarboxylation and delta-8 THC
Approximate price	$40 to $50	$129.99

OilWell RSO vs. Traditional Illegal RSO

Dimension	Traditional RSO	OilWell formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None — every batch different	Lab-tested with specific mg/mL targets
Lab testing	Not available or performed	Full panel testing
Residual solvents	Significant risk with naphtha	Controlled and tested
Dosing precision	Approximate, syringe-based	Measured per mL with known cannabinoid content (553 mg/mL)
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	No — fully decarboxylated by heat	Yes — THCa included as a separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Condition-Specific Usage Context

Important disclaimer: The following usage contexts are informed by cannabinoid research and our formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not a substitute for professional medical care. These products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have any health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Chemotherapy-related nausea and appetite support:

• Pre-chemo: 0.5 to 1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2 to 3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0 to 2.0 mL sublingual before bed (delivers 25 to 50 mg CBN)
• Evidence context: delta-8 THC antiemetic evidence, delta-9 THC nausea and vomiting evidence, CBD anxiolytic buffering

Chronic pain (fibromyalgia, arthritis, neuropathy):

• Daytime: 0.3 to 0.5 mL raw sublingual; provides anti-inflammatory cannabinoid exposure without psychoactive impairment
• Nighttime: 0.5 to 1.0 mL decarboxylated sublingual; combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset
• Evidence context: CBD pain evidence, delta-9 THC pain evidence, beta-caryophyllene CB2 agonism, THCa COX-2 inhibition

Sleep support:

• Before bed: 1.0 to 2.0 mL sublingual
• At 2.0 mL, this delivers 50 mg CBN — the dosage level investigated in the 2024 sleep literature
• At 1.0 mL, this delivers 25 mg CBN — above the 20 mg threshold associated with reduced sleep disturbance in published research
• Evidence context: CBN sleep evidence, cannabis and sleep review literature

Anxiety and stress:

• Daytime functional relief: 0.3 mL raw sublingual; CBD and CBG address anxiety-related pathways without psychoactive impairment
• Nighttime: 1.0 mL sublingual; full cannabinoid profile including CBN for sleep architecture
• Evidence context: CBD anxiety evidence, CBG pharmacology, limonene entourage-effect evidence

General titration principle: Start low, go slow. Begin with 0.25 to 0.5 mL sublingual and assess effects over 2 to 3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors.

Delivery and Accessibility: How Texans Get Our Products

We operate the only same-day RSO delivery system in Houston. Beyond Houston, we ship nationwide and internationally.

Houston same-day delivery:

Zone	Coverage	Delivery fee	Typical turnaround
Texas Medical Center	All 60+ TMC institutions (MD Anderson, Memorial Hermann, Methodist, Texas Children’s, St. Luke’s, and more)	FREE	2 to 4 hours
Inner Loop (610)	Downtown, Midtown, Montrose, Heights, Rice Village, Museum District, River Oaks, Upper Kirby, Galleria	$5	2 to 4 hours
Within Beltway 8	Bellaire, Memorial, Spring Branch, South Houston, Pasadena (partial), Hobby Airport area	$10	3 to 5 hours
Greater Houston suburbs	Katy, Sugar Land, Pearland, Clear Lake, Woodlands, Cypress, Tomball, Humble, Kingwood	$15	4 to 6 hours
Extended region (60 miles)	Galveston, Baytown, Rosenberg, Conroe, La Porte, Seabrook	$20 to $25	Same-day if ordered before 2 PM

Free delivery to the Texas Medical Center, the world’s largest medical complex with over 10 million patient visits annually, reflects our commitment to accessibility for the patients who need it most.

Nationwide shipping:

• All 50 states where Farm Bill-compliant products are legal
• USPS Priority Mail (2 to 3 business days), FedEx and UPS Ground (3 to 5 business days)
• Discreet packaging with no cannabis branding visible
• Tracking provided for all orders
• Temperature-stable packaging for summer shipments
• Signature-required option available

International shipping:
We ship internationally and have already delivered to multiple countries across multiple continents. The THCa legal framework makes this possible: because the product contains less than 0.3 percent delta-9 THC at the point of sale, it meets the definition of a hemp-derived product under the 2018 Farm Bill and is shippable to jurisdictions with compatible hemp laws.

• All international packages include full documentation, Certificates of Analysis (COAs), and receipts for customs purposes
• Minimum flat-fee shipping applies; excessive international shipping costs are billed to the customer
• You are responsible for verifying legality in your jurisdiction and accept all customs and legal risk
• Contact: (832) 416-2816 or [email protected]

The significance of international access cannot be overstated. Rick Simpson couldn’t ship his oil anywhere; it was Schedule I, illegal to produce, possess, or transport. A cancer patient in Germany, a chronic pain patient in Australia, or a veteran in the United Kingdom can now potentially access the same multi-cannabinoid RSO formula that a Houston resident receives via same-day delivery. We built a product that can move across borders legally, completing a piece of Rick Simpson’s vision that prohibition made impossible during his lifetime of advocacy.

Research Limits and Honest Interpretation

We want to be completely clear about what the evidence does and does not support. The evidence base is highly uneven. CBD and delta-9 THC can support the most detailed human-facing statements; the rest require more caution. Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, and terpene-only data are not interchangeable. One common error in cannabis writing is to let evidence from one category stand in for another.

Minor cannabinoids and terpenes are commercially interesting precisely because they are underexplored, but that also means the claims around them often become inflated. Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability, and route-dependent pharmacokinetics all materially affect interpretation in real-world products.

For THCa in particular, chemistry is destiny: storage and heating can change the actual exposure profile by converting acidic cannabinoids into neutral cannabinoids such as THC.

Common overstatements to avoid:

• Overstatement: CBN is a clinically proven sleep cannabinoid.
  More accurate: The specific sleep evidence for CBN remains weak and dated, with no strong validated-trial base yet identified.

• Overstatement: Myrcene is a proven human sedative that reliably explains couch-lock.
  More accurate: Myrcene has plausible preclinical bioactivity, but direct human proof for that common claim is limited.

• Overstatement: Terpenes in general have proven entourage effects in patients.
  More accurate: Entourage hypotheses are influential and worth studying, but robust clinical proof remains limited and highly compound-specific.

• Overstatement: THCa is always non-psychoactive.
  More accurate: THCa itself is not THC, but heating and processing can convert THCa into THC, changing the effective exposure.

• Overstatement: Delta-8 THC is safe because it is hemp-derived.
  More accurate: Delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, and often entangled with manufacturing and testing concerns.

The most evidence-developed actives in our formulas are CBD and delta-9 THC. Delta-8 THC is not a trivial or purely mild ingredient; it is a psychoactive cannabinoid with less robust safety and efficacy characterization than delta-9 THC. THCa meaningfully changes with processing and should not be interpreted the same way in raw, gently handled, and heated formats. CBG, CBN, and CBC are scientifically credible but clinically immature compared with CBD and THC. The listed terpenes are likely highly relevant to aroma, flavor, and potentially some biologic activity, but compound-specific human therapeutic claims should be made carefully and only where directly supported.

Simpson’s Claims vs. The Evidence Record

Rick Simpson made expansive therapeutic claims about his oil. He stated that RSO could cure cancer (including terminal cases) and that it was effective against diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, multiple sclerosis, and numerous other conditions. It’s important to evaluate these claims against the actual evidence base, using the same standards we apply throughout this document.

What Simpson was not: Simpson was not a scientist, physician, pharmacologist, or researcher. He had no formal training in medicine, oncology, pharmacology, or clinical research methodology. He never designed, conducted, funded, or published a clinical trial. He never submitted his results to peer review. His entire evidence base consisted of personal experience, self-reported patient outcomes, and testimonials gathered informally, with no controls, no independent verification, no imaging confirmation, no long-term follow-up, and no blinding.

What the preclinical literature shows: In vitro studies have demonstrated that THC and CBD can induce apoptosis (programmed cell death), inhibit proliferation, and reduce angiogenesis (blood vessel formation that feeds tumors) in certain cancer cell lines. Animal model studies have shown some tumor-growth inhibition in mice and rats treated with cannabinoids. These findings have generated legitimate scientific interest and ongoing research.

What the preclinical literature does not show: These findings have not translated into proven human cancer cures. The gap between in vitro or animal results and human clinical outcomes is vast, well-documented across all of oncology research, and especially relevant here. No human clinical trial has demonstrated that RSO or any cannabis oil preparation cures cancer. Several small human trials of cannabinoids in cancer contexts (particularly glioblastoma) have been conducted, but they have been exploratory, small, and have not produced the kind of results that would support cancer-cure claims.

Institutional positions: The U.S. National Cancer Institute (NCI) acknowledges that cannabinoids have been studied for potential anticancer effects in laboratory and animal models but does not endorse cannabis or cannabis oil as a cancer treatment. The U.S. Food and Drug Administration (FDA) has not approved any cannabis plant product for the treatment of cancer. The only FDA-approved cannabinoid-related products are for other specific indications: Epidiolex (CBD) for certain seizure disorders and dronabinol/nabilone (synthetic THC analogues) for chemotherapy-related nausea and AIDS-related wasting. NCCIH explicitly states that the strongest cannabinoid evidence is for rare epilepsies, chemotherapy-related nausea and vomiting, and appetite-related indications in HIV/AIDS, not cancer cure.

What Simpson got right: He drew attention to cannabinoids as a serious area of biomedical research at a time when most of the world was ignoring or actively suppressing that conversation. His advocacy, however scientifically imprecise, helped create the political, cultural, and social conditions for the legal cannabis industry and the cannabinoid research infrastructure that exists today. He was among the first to bring concentrated cannabis oil to widespread public awareness, and the term RSO itself remains the most recognized name for full-spectrum cannabis extract in the consumer vocabulary. These contributions are real and historically significant.

What he overstated: The leap from preclinical signals to cancer cure was not supported by human evidence when Simpson made it, and it is not supported now. Encouraging patients, particularly cancer patients, to rely on RSO as a primary treatment in place of proven oncologic therapies (surgery, radiation, chemotherapy, immunotherapy) carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern in the alternative-medicine literature. Simpson’s absolute certainty about curative claims, while understandable from a personal-experience perspective, exceeded what the evidence could support and still exceeds it today.

How Our Formulas Connect to the Evidence

Every cannabinoid in our formula (CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC) has its own evidence profile documented in this document. Every terpene (limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene) is covered with preclinical and review-level evidence. The formulas published here are not standalone product listings. They are anchored to per-compound evidence summaries that explain what is well-supported by human clinical data, what is emerging from review and preclinical literature, and what is overstated relative to the current evidence base. Where our RSO guide page makes specific research claims about individual cannabinoids or terpenes, this document provides the source evaluation context (the same peer-reviewed citations, the same evidence-tier assessments, and the same cautious interpretation framework).

The evidence hierarchy, overstatement warnings, and safety notes apply equally to our own products. This document does not exempt OilWell from the same evidence standards applied to the broader cannabinoid field. That is intentional. Our position, as stated by Colin Valencia in 2019, is that people deserve the best possible version of the information so they can give it a fair shot and decide for themselves whether it is right or wrong for them. This document is the research foundation for that position.

The Broader OilWell Product Portfolio

Beyond RSO, we produce a range of cannabinoid products, each developed from the formulation knowledge Colin built over Bentley’s ten-year journey and his own experience with PTSD and benzo withdrawal.

Asshole Peach Gummy Rings ($39.99) — Our most popular product. Asshole Peach is a carefully formulated experience designed to provide a euphoric, long-lasting sensation. It is particularly favored by veterans for its ability to relieve pain and PTSD symptoms without being overly aggressive. Each ring contains 268mg total cannabinoids: 28mg Delta-9 THC, 50mg Delta-8 THC, 20mg Delta-10 THC, 20mg THCo, 100mg CBD, and 50mg CBG.

Peace Gummy Peaches ($34.99) — Developed directly from Colin’s own experience with PTSD and benzodiazepine addiction. Peace Gummies helped him quit Xanax cold turkey. The formula is also available in a vape form for quick relief. Each peach contains 320mg total cannabinoids: 30mg CBN, 15mg Delta-9 THC, 25mg Delta-8 THC, 100mg CBD, and 150mg CBG.

SWEETEMintz Sugar-Free Vegan Peppermint Hard Candy ($39.99) — 28mg Delta-9 Nano THC, 100mg Nano CBD, 50mg CBG Isolate. Zero sugar, 100% vegan, designed for diabetic and health-conscious consumers.

Custom creations — We design tailored products on request for specific cannabinoid ratios, delivery formats, or health circumstances, including formulations for vegans, diabetics, and those with specific dietary needs.

Media Recognition and Community Impact

Between September 2019 and April 2023, ABC13 Houston (KTRK), the ABC affiliate serving the fourth-largest city in the United States, featured Colin Valencia and OilWell Cannabis in seven distinct news segments spanning business, law, medicine, community health, and politics. Five different ABC13 reporters sought Colin out across those years: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers. No other Houston cannabis operator appears with that frequency or across that breadth of subject matter during the same period.

September 2019: “Texas CBD businesses booming as industry continues to evolve” — The earliest documented ABC13 feature on OilWell and the origin point of our foundational philosophy. That Colin quote from 2019, years before the formulas in this document were published, is the seed of everything OilWell would become. The open-source formula publication, the evidence-based research documentation, the refusal to make unsupported claims: it all traces back to his principle that people deserve honest education, not snake oil or false hope.

March 2021: “Entrepreneur creates direct-to-consumer business ahead of marijuana decriminalization efforts” — Colin as ecosystem builder, helping other entrepreneurs like Jonathan Pina enter the legal cannabis space. His therapy quote, “pain comes in a lot of different forms,” went deeper than any prior interview into the therapeutic dimension.

May 2021: “What is Delta 8 THC and why is it considered legal weed in Texas” — This investigative feature became one of the most widely referenced ABC13 cannabis segments. The exchange between Steve Campion and Colin, “Maybe you want to get high,” became one of his most iconic media moments: radical honesty on mainstream television with the expletive preserved by the network.

August 2021: “Houston CBD shop giving away free products to those who get COVID vaccine” — Approximately $35,000 in product (1,000 caviar pre-rolls at $34.99 each) donated to encourage COVID-19 vaccination. No political strings attached. Just real product and real coordination with city government to help during a public health crisis.

October 2021: “Texas ban over once legal hemp product Delta 8 raises questions over legality” — A defining moment. Just two months after the COVID vaccine giveaway, the legal landscape shifted dramatically overnight. Shelley Childers went directly to the OilWell dispensary and found that Colin had already removed all Delta-8 products from his shelves, proactively, before enforcement began, and before most of the industry even knew the change had happened. Colin had been trying to spread the word himself to other operators who were unknowingly shipping what had overnight become Schedule I narcotics.

October 2022: “Biden marijuana pardon — Texas won’t see impact” — The feature brought the most personal dimension of Colin’s story into public view. The article revealed that Colin has previously faced charges for marijuana possession. That personal history transforms the entire media record. Every feature, every quote about therapy, about education, about not selling snake oil, all carry additional weight when you understand that the person saying it has personally experienced the consequences of cannabis criminalization. The CBD vending machine debut showed continued innovation in accessibility.

April 2023: “‘I want it to be legalized’: Marijuana industry getting creative as Texas laws continue to change” — The most recent ABC13 feature, published the day after 4/20, completes a four-year arc. Colin’s “Renaissance” framing reframed the present as opportunity rather than waiting. From the September 2019 CBD business profile through the Delta-8 boom and bust, the COVID community initiative, the personal revelation of cannabis conviction history, and now the “Renaissance” framing, Colin Valencia’s media trajectory mirrors the trajectory of legal cannabis in Texas itself.

These features are not marketing materials. They are independently produced, editorially controlled news segments from a major-market ABC affiliate that repeatedly identified Colin Valencia as the most credible, most quotable, and most accessible voice in Houston’s legal cannabis industry. That is the kind of recognition that cannot be purchased; it can only be earned.

Business Hours and Contact Information

Hours:

• Monday through Thursday: 10:00 AM to 7:00 PM
• Friday through Saturday: 10:00 AM to 10:00 PM
• Sunday: 10:00 AM to 4:00 PM

Contact:

• Phone: (832) 416-2816
• Email: [email protected]
• Website: https://oilwellcbd.com/
• Instagram: @oilwellcbd
• Address: 810 Richmond Ave, Houston, TX 77006 (Montrose neighborhood)

Final Word: What We Believe

We’ve built OilWell Cannabis on a simple foundation: Texans deserve honest information, properly formulated products, and accessible pathways to cannabinoid support. Whether you’re a cancer patient seeking adjunctive care beyond what TCUP offers, a chronic pain patient who doesn’t qualify for the state program, a veteran managing PTSD, someone struggling with sleep or anxiety, or simply curious about what multi-cannabinoid formulation might offer you; we’re here with transparency about what the evidence supports, what the evidence doesn’t support, and what we’ve learned from real-world formulation experience.

The RSO tradition began with a man who gave away his oil and taught others to make it themselves. We’ve adapted that ethos for the modern world: professionally manufactured products with published formulas for those who can afford them, and open-source recipes for those who want to formulate their own. That principle, making cannabinoid support accessible regardless of economic circumstance, is why open-source matters to us. It’s why we publish everything.

We don’t pretend cannabis is right for everyone. What we do believe is that people deserve access to the best available version of the information, the best available version of the product, and the ability to make their own informed decisions. That’s what this document provides: the complete picture, evidence and limitations and all, so you can decide for yourself.

References:

1. National Center for Complementary and Integrative Health. Cannabis Marijuana and Cannabinoids: What You Need To Know. NIH/NCCIH. Accessed March 2026.
2. Talwar A, Estes E, Aparasu R, Reddy DS. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Exp Neurol. 2023;359:114238.
3. Han K, Wang JY, Wang PY, Peng YC. Therapeutic potential of cannabidiol CBD in anxiety disorders: A systematic review and meta-analysis. Psychiatry Res. 2024;339:116049.
4. Cásedas G, Yarza-Sancho M, López V. Cannabidiol CBD: A systematic review of clinical and preclinical evidence in the treatment of pain. Pharmaceuticals Basel. 2024;17(11):1438.
5. Ranum RM, Whipple MO, Croghan I, Bauer B, Toussaint LL, Vincent A. Use of cannabidiol in the management of insomnia: A systematic review. Cannabis Cannabinoid Res. 2023;8(2):213-229.
6. Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. J Intern Med. 2023;293(6):724-752.
7. Nachnani R, Raup-Konsavage WM, Vrana KE. The pharmacological case for cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204-212.
8. Li S, Li W, Malhi NK, et al. Cannabigerol CBG: A comprehensive review of its molecular mechanisms and therapeutic potential. Molecules. 2024;29(22):5471.
9. Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol delta8 THC: Comparative pharmacology with delta9 THC. Br J Pharmacol. 2022;179(15):3915-3933.
10. LoParco CR, Rossheim ME, Walters ST, et al. Delta-8 tetrahydrocannabinol: A scoping review and commentary. Addiction. 2023;118(6):1011-1028.
11. Abdel-Kader MS, Radwan MM, Metwaly AM, et al. Chemistry and pharmacology of Delta-8-Tetrahydrocannabinol. Molecules. 2024;29(6):1249.
12. Moreno-Sanz G. Can You Pass the Acid Test? Critical review and novel therapeutic perspectives of delta9-Tetrahydrocannabinolic Acid A. Cannabis Cannabinoid Res. 2016;1(1):124-130.
13. McDonagh MS, Morasco BJ, Wagner J, et al. Cannabis-based products for chronic pain: A systematic review. Ann Intern Med. 2022;175(8):1143-1153.
14. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-360.
15. Rittiphairoj T, Leslie L, Oberste JP, et al. High-concentration delta-9-tetrahydrocannabinol cannabis products and mental health outcomes: A systematic review. Ann Intern Med. 2025;178(10):1429-1440.
16. Corroon J. Cannabinol and sleep: Separating fact from fiction. Cannabis Cannabinoid Res. 2021;6(5):366-371.
17. Lavender I, Garden G, Grunstein RR, et al. Using cannabis and CBD to sleep: An updated review. Curr Psychiatry Rep. 2024;26(12):712-727.
18. Sepulveda DE, Vrana KE, Kellogg JJ, et al. The potential of cannabichromene as a therapeutic agent. J Pharmacol Exp Ther. 2024;391(2):206-213.
19. Zagožen M, Čerenak A, Kreft S. Cannabigerol and cannabichromene in Cannabis sativa L. Acta Pharm. 2021;71(3):355-364.
20. André R, Gomes AP, Pereira-Leite C, et al. The entourage effect in cannabis medicinal products: A comprehensive review. Pharmaceuticals Basel. 2024;17(11):1543.
21. Anandakumar P, Kamaraj S, Vanitha MK. D-limonene: A multifunctional compound with potent therapeutic effects. J Food Biochem. 2021;45(1):e13566.
22. Ogueta IA, Brared Christensson J, Giménez-Arnau E, et al. Limonene and linalool hydroperoxides review: Pros and cons for routine patch testing. Contact Dermatitis. 2022;87(1):1-12.
23. Surendran S, Qassadi F, Surendran G, et al. Myrcene: What are the potential health benefits of this flavouring and aroma agent? Front Nutr. 2021;8:699666.
24. Hashiesh HM, Sharma C, Goyal SN, et al. A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of beta-caryophyllene, a dietary cannabinoid. Biomed Pharmacother. 2021;140:111639.
25. Weston-Green K, Clunas H, Jimenez Naranjo C. A review of the potential use of pinene and linalool as terpene-based medicines for brain health. Front Psychiatry. 2021;12:583211.
26. Dos Santos ÉRQ, Maia JGS, Fontes-Júnior EA, do Socorro Ferraz Maia C. Linalool as a therapeutic and medicinal tool in depression treatment: A review. Curr Neuropharmacol. 2022;20(6):1073-1092.
27. Dalavaye N, Nicholas M, Pillai M, et al. The clinical translation of alpha-humulene: A scoping review. Planta Med. 2024;90(9):664-674.
28. Menezes IO, Scherf JR, Martins AOBPB, et al. Biological properties of terpinolene evidenced by in silico, in vitro and in vivo studies: A systematic review. Phytomedicine. 2021;93:153768.
29. Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364.